Teenagers and young adults with cancer in Europe: from national programmes to a European integrated coordinated project

Stark, Dan; Bielack, Stefan; Brugières, Laurence; Dirksen, Uta; Duarte, Ximo; Sm, Dunn; Erdélyi, Dániel; Grew, Tom; Hjorth, Lars; Jazbec, Janez; Kabíčková, Edita; Konsoulova, Assia; Kowalczyk, Jerzy; Lassaletta, Álvaro; Laurence, Valérie; Lewis, I; Monrabal, A.; Morgan, Sue; Mountzios, Giannis; Olsen, Pia Riis; Renard, Marleen; Sæter, Gunnar; Graaf, Winette Ta van der; Ferrari, Andrea

doi:10.1111/ecc.12365

Cited by 85 publications

(81 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adolescents and young adults (AYA) comprise a group aged between 15 and 39 years . It is becoming increasingly apparent that AYA with cancer harbor a broad spectrum of cancer types with unique tumor biology, and a different behavior from younger or older patients . Oncological care of these patients is typically not uniform as they frequently fall between the pediatric and adult services.…”

Section: Introductionmentioning

confidence: 99%

Adolescents and young adults with brain tumors in the context of molecular advances in neuro‐oncology

Zápotocký

Ramaswamy

Lassaletta

et al. 2017

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Adolescents and young adults (AYA) comprise a specific group of oncology patients with a distinct biological and epidemiological spectrum of central nervous system neoplasms. It has been well documented that they differ clinically, especially in relation to prognosis and chemotherapy tolerance; however, the underlying reasons for this are unclear. Recent advances in the genomics of both childhood and adult brain tumors have provided new explanations and insights into the previously described age-dependent heterogeneity. Herein, we summarize the current state of the AYA population in neuro-oncology, specifically how biological advances can help personalize therapy for this unique group of patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Adolescents and young adults with brain tumors in the context of molecular advances in neuro‐oncology

Zápotocký

Ramaswamy

Lassaletta

et al. 2017

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…The development of TYA specialist cancer care is beginning to appear in many European countries [32]. In addition to examining survival outcomes it is also important to quantify differences in the quality of care and patient experience.…”

Section: Discussionmentioning

confidence: 99%

Access to principal treatment centres and survival rates for children and young people with cancer in Yorkshire, UK

et al. 2017

View full text Add to dashboard Cite

BackgroundPrincipal Treatment Centres (PTC) were established to provide age-appropriate care as well as clinical expertise for children and young people with cancer. However, little is known about the effects of specialist treatment centres on survival outcomes especially for teenagers and young adults. This population-based study aimed to describe access to PTC and the associated trends in survival for 0–24 year olds accounting for stage of disease at presentation and treatment.MethodsPatients diagnosed from 1998–2009 aged 0–24 years were extracted from the Yorkshire Specialist Register of Cancer in Children and Young People, including information on all treating hospitals, followed-up until 31st December 2014. The six commonest cancer types were included: leukaemia (n = 684), lymphoma (n = 558), CNS tumours (n = 547), germ cell tumours (n = 364), soft tissue sarcomas (n = 171) and bone tumours (n = 163). Treatment was categorised into three groups: ‘all’, ‘some’ or ‘no’ treatment received at a PTC. Treatment at PTC was examined by diagnostic group and patient characteristics. Overall survival was modelled using Cox regression adjusting for case-mix including stage, treatment and other socio-demographic and clinical characteristics.ResultsOverall 72% of patients received all their treatment at PTC whilst 13% had no treatment at PTC. This differed by diagnostic group and age at diagnosis. Leukaemia patients who received no treatment at PTC had an increased risk of death which was partially explained by differences in patient case-mix (adjusted Hazard Ratio (HR) = 1.73 (95%CI 0.98–3.04)). Soft tissue sarcoma patients who had some or no treatment at PTC had better survival outcomes, which remained after adjustment for patient case-mix (adjusted HR = 0.48 (95%CI 0.23–0.99)). There were no significant differences in outcomes for other diagnostic groups (lymphoma, CNS tumours, bone tumours and germ cell tumours). For leukaemia patients survival outcomes for low risk patients receiving no treatment at PTC were similar to high risk patients who received all treatment at PTC, implying a benefit for care at the PTC.ConclusionThis study demonstrates that for leukaemia patients receiving treatment at a PTC is associated with improved survival that may compensate for a poorer prognosis presentation. However, further information on risk factors is needed for all diagnostic groups in order to fully account for differences in patient case-mix.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-017-3160-5) contains supplementary material, which is available to authorized users.

show abstract

“…Outcomes are often poorer than in younger patients with the same cancer, and several contributory factors have been identified: the type of tumours, their biology and sensitivity to current therapies, as well as the low participation of TYA in clinical trials [14] [15]. TYA have specific and unmet needs, including complex psychological and social supportive care.…”

Section: Objective 5: Teenagers and Young Adultsmentioning

confidence: 99%

“…Within ENCCA a pilot project has been initiated in order to build the European Network for Teenagers and Young Adults Cancer [14].…”

Section: Actionsmentioning

confidence: 99%

The SIOPE strategic plan: A European cancer plan for children and adolescents

Vassal

Schrappe

Pritchard‐Jones

et al. 2016

Journal of Cancer Policy

View full text Add to dashboard Cite

Executive summaryCancer in young people is rare, but it is still a major health issue in Europe. Each year, more than 6,000 young people in Europe die of cancer. There are more than 300,000 European childhood cancer survivors (in 2020, they will be nearly half a million): two-thirds of them have some late side effects of treatment, that are severe and impact on the daily life of half of those affected.Within the European Network for Cancer research in Children and Adolescents (ENCCA), SIOPE and the European paediatric haematology-oncology community have established a long-term sustainable Strategic Plan to increase the cure rate and the quality of survivorship for children and young people with cancer over the next ten years. The ultimate goal is to increase the disease-and late-effect-free survival after 10 years from the diagnosis, and beyond.

show abstract

Teenagers and young adults with cancer in Europe: from national programmes to a European integrated coordinated project

Cited by 85 publications

References 61 publications

Adolescents and young adults with brain tumors in the context of molecular advances in neuro‐oncology

Adolescents and young adults with brain tumors in the context of molecular advances in neuro‐oncology

Access to principal treatment centres and survival rates for children and young people with cancer in Yorkshire, UK

The SIOPE strategic plan: A European cancer plan for children and adolescents

Contact Info

Product

Resources

About